Note: This document contains side effect information about nilutamide. Some of the dosage forms listed on this page may not apply to the brand name Nilandron.
Common side effects of Nilandron include: nausea, night blindness, and decreased libido. Other side effects include: chest pain, fever, hemeralopia, visual disturbance, chromatopsia, and loss of body hair. See below for a comprehensive list of adverse effects.
Applies to nilutamide: oral tablet
Oral route (Tablet)
Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials of nilutamide. Reports of interstitial changes including pulmonary fibrosis that led to hospitalization and death have been reported rarely post-marketing. Symptoms included exertional dyspnea, cough, chest pain, and fever. A routine chest X-ray should be performed prior to initiating treatment and baseline pulmonary function tests may be considered. Patients should be instructed to report any new or worsening shortness of breath, and if symptoms occur, nilutamide should be discontinued until it can be determined if the symptoms are drug-related.
Along with its needed effects, nilutamide (the active ingredient contained in Nilandron) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking nilutamide:
Some side effects of nilutamide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to nilutamide: oral tablet
Very common (10% or more): Dyspnea (up to 10.5%)
Common (1% to 10%): Interstitial pneumonitis, lung disorder, upper respiratory infection, pneumonia, increased cough, rhinitis
Postmarketing reports: Interstitial or alveolo-interstitial changes (e.g. pulmonary fibrosis)
Very common (10% or more): Increased AST (up to 12.9%)
Common (1% to 10%): Increased ALT, increased alkaline phosphatase, increased BUN, increased creatinine
Uncommon (0.1% to 1%): Hepatitis
Rare (less than 0.1%): Mixed hepatocellular-fulminant hepatitis
Very common (10% or more): Impaired adaptation to dark (up to 57%)
Common (1% to 10%): Chromatopsia, impaired adaptation to light, abnormal vision, cataract, photophobia
Common (1% to 10%): Hypertension, angina, heart failure
Frequency not reported: QT prolongation
Common (1% to 10%): Anemia, hematuria, melena, increased haptoglobin, leukopenia
Rare (less than 0.1%): Aplastic anemia
The most common adverse events (especially nausea, alcohol intolerance, impairment of dark or light adaptation and dizziness) occur early during treatment and usually lessen after one month following dose reduction.
Very common (10% or more): Hot flushes (up to 66.5%), impotence (up to 11%), decreased libido (up to 11%), gynecomastia (up to 10.5%)
Common (1% to 10%): Sweating, body hair loss
Very common (10% or more): Testicular atrophy (up to 16.3%)
Common (1% to 10%): Urinary tract infection, urinary tract disorder, nocturia
Very common (10% or more): Pain (up to 26.8%), asthenia (up to 19.1%), peripheral edema (up to 12.4%), alcohol intolerance (up to 10%)
Common (1% to 10%): Chest pain, fever, flu syndrome, malaise, syncope
Very common (10% or more): Headache (up to 13.9%), dizziness (up to 10%)
Common (1% to 10%): Hypesthesia, paresthesia, nervousness
Very common (10% or more): Anorexia (up to 11%)
Common (1% to 10%): Weight loss, hyperglycemia
Very common (10% or more): Back pain (up to 11.5%)
Common (1% to 10%): Bone pain, arthritis
Very common (10% or more): Insomnia (up to 16.3%)
Common (1% to 10%): Depression
Very common (10% or more): Nausea (up to 23.9%), constipation (up to 19.6%), abdominal pain (up to 10%)
Common (1% to 10%): Dyspepsia, vomiting, diarrhea, gastrointestinal disorder, gastrointestinal hemorrhage, dry mouth
Common (1% to 10%): Dry skin, rash, pruritus
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Nilandron